The Latin America In Vitro Diagnostics (IVD) Market will grow at a CAGR of 5.5% during the forecast period to reach $6.45 billion by 2030 from $4.44 billion in 2023, Says ‘Meticulous Research®. The Latin America in vitro diagnostics (IVD) market includes consumables like kits & reagents, instruments, software & services. Factors such as the increasing prevalence of communicable and non-communicable diseases, rising medical tourism, a shift towards decentralized testing, and growing awareness regarding early disease diagnosis are driving the growth of the Latin America IVD market.
Here are the top 10 companies operating in the Latin America In Vitro Diagnostics Market
Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche is engaged in developing medicines to improve the standard of healthcare. The company operates through two divisions – Pharmaceuticals and Diagnostics. The company offers centralized and point of care kits & reagents, advanced staining reagents, molecular diagnostic tests, and blood screening tests through its Diagnostics division.
The Diagnostics segment is further categorized into Core Lab, Molecular Lab, Point of Care, Diabetes Care, and Pathology Lab. The Diagnostics division manufactures equipment & reagents for research & medical diagnostic applications.
Roche has 20 manufacturing sites and 27 R&D sites worldwide that are engaged in pharmaceutical and diagnostic operations. In Latin America, Roche has its presence across Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Mexico, and other countries through its subsidiaries and associates.
Abbott Laboratories (U.S.)
Founded in 1888 and headquartered in Illinois, U.S., Abbott Laboratories is engaged in the discovery, development, manufacturing, and sale of a comprehensive range of healthcare products. The company offers a wide range of products in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The company operates through four business segments – Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company operates in the IVD market through the Diagnostics business segment, further divided into major business categories – Core Laboratory, Rapid Diagnostics, Point of Care, and Molecular.
The company has a wide geographic presence and a strong distribution network globally through its 90 manufacturing facilities. Of these, 24 manufacturing sites are engaged in developing diagnostic products.
Founded in 1969 and headquartered in Washington, U.S., Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products & services. The company operates through three business segments – Life Sciences, Diagnostics, and Environmental & Applied Solutions. Danaher offers a wide range of products in the diagnostics market, including analytical instruments, reagents, consumables, software, and services that are used in various healthcare settings such as hospitals, physicians’ offices, reference laboratories, and other critical care settings for diagnosis of diseases.
The company’s Diagnostics segment is categorized into Clinical Lab Diagnostics, Critical Care Diagnostics, and Anatomical & Pathological Diagnostics.
Danaher Corporation has 212 R&D, manufacturing, sales, distribution, service, and administrative facilities in more than 60 countries worldwide. The company’s manufacturing facilities are located in North America, Europe, Asia, and Australia.
Siemens Healthineers AG (Germany)
Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG is engaged in developing and selling a wide range of products with medical imaging applications, laboratory diagnostics, and point of care testing. The company also offers digital health platforms for various clinical specialties and laboratories across the globe.
The company operates in four business segments – Imaging, Diagnostics, Varian, and Advanced Therapies. The company operates in the IVD market through its Diagnostics segment, offering in vitro diagnostic products & services to healthcare professionals working in molecular diagnostics, point of care diagnostics, and laboratories.
The company has a direct presence in more than 70 countries, including the U.S., Canada, Germany, the U.K., France, Italy, Spain, Denmark, Sweden, Switzerland, Belgium, India, China, Japan, Australia, New Zealand, and the Republic of Korea.
Founded in 1897 and headquartered in New Jersey, U.S., Becton, Dickinson and Company (BD) is a medical technology company engaged in the development, manufacture, and sale of a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company operates through three business segments – BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences business segment offers products through two major categories – Integrated Diagnostic Solutions (Diagnostic Systems and Preanalytical Systems) and Biosciences.
The Diagnostic Systems category provides numerous products with clinical and industrial applications. These products include molecular testing systems for infectious diseases & women’s health, liquid-based cytology systems for cervical cancer screening, culturing systems, rapid diagnostic assays for testing respiratory infections, microorganism identification, and drug susceptibility systems.
The primary customers served by the BD Life Sciences segment are hospitals, laboratories & clinics, blood banks, healthcare workers, public health agencies, physicians’ offices, retail pharmacies, academic & government institutions, and pharmaceutical & biotechnology companies.
BD has a direct presence in the U.S., Brazil, Canada, China, France, Spain, the U.K., Germany, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, the Netherlands, and Singapore through its manufacturing and sales operations. The R&D facilities of the company are located globally, including in China, France, India, Ireland, the U.S., and Singapore. The company also has a wide distribution network across the globe.
Meticulous Research in its latest publication on Latin America In Vitro Diagnostics Market has predicted the growth of 5.5% during the forecast year 2023-2030.
bioMérieux SA (France)
Founded in 1963 and headquartered in Marcy l’Etoile, France, bioMérieux is engaged in developing a wide range of products & solutions, including reagents, instruments, and software for clinical diagnostics. The company offers products for microbiology, immunoassay, molecular biology, and industrial applications. In the clinical field, the company’s products are used for infectious disease diagnostics, while in the industrial field, products are used to detect microorganisms in agri-food, pharmaceuticals, and cosmetics.
The company’s major products under molecular biology solutions include BIOFIRE FILMARRAY molecular biology solutions, VIDAS B∙R∙A∙H∙M∙S PCT test, VITEK range, and ARGENE range.
The company has a direct presence and a strong distribution network across 160 countries through 44 subsidiaries and 15 production sites. The company has a fully-owned production site in Jacarepagua (Brazil). The activities carried out at this site are production, sales, and distribution of reagents for ready-to-use media in microbiology (Petri dishes and the CHROMID range) and industrial applications; research & development; commercial and administrative functions.
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific provides analytical instruments, laboratory equipment, laboratory services, and diagnostics instruments. The company operates through four business segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
The company offers IVD solutions through its Specialty Diagnostics segment. In June 2019, Thermo Fisher Scientific sold its Anatomical Pathology business to PHC Holdings Corporation (Japan), which offered cancer diagnosis and medical research products for histology, cytology, and hematology applications.
The company has a direct presence through its regional offices and production sites in various countries, including the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea.
QIAGEN N.V. (Netherlands)
QIAGEN N.V. develops & sells instruments, consumables, and digital bioinformatics solutions for oncology, infectious diseases, sexual & reproductive health, tuberculosis management, precision diagnostics, and point of care testing. The company operates in two business segments – Molecular Diagnostics and Life Sciences. Qiagen N.V. offers a wide range of molecular diagnostic technologies through its molecular diagnostics business segment, including automated systems, assays, markers, and reagents used to diagnose cancer and infectious diseases.
QIAGEN N.V. offers its products to more than 500,000 customers and has 35 subsidiaries operating in 35 countries, including the U.S., Canada, Germany, Spain, the U.K., France, Italy, the Netherlands, Sweden, Turkey, Sweden, Brazil, Mexico, China, Hong Kong, Taiwan, South Korea, India, and South Africa. The company has a strong distribution network with distribution partners spread across 60 countries.
Wama Diagnóstica is engaged in the research, development, and production of kits & reagents for laboratory diagnostics, especially immunodiagnostics. The company also manufactures immuno-chromatographic tests (Lateral Flow) and urine strips. The company is certified by BSI in ISO 13485 and ISO 9001 standards, by ANVISA in GMP (Good Manufacturing Practices for in vitro Diagnostic Kits and Laboratory Equipment) and has CE marking on a majority of its products. In the diagnostics market, the company offers reagents & kits, and instruments. Wama Diagnóstica is a privately held company.
Wiener Laboratorios SAIC (Argentina)
Wiener Laboratorios SAIC deals in clinical & specialized laboratories and blood banks. Wiener offers diagnostic products such as kits & analyzers for clinical chemistry, hematology, coagulation, and immunology assays. The company offers its products to researchers, technicians, and qualified professionals.
The company has a manufacturing facility in Venezuela, and affiliate companies in Brazil, Chile, Colombia, Costa Rica, Mexico, Peru, Uruguay, and the Dominican Republic. The company has distributors across Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Poland, Dominican Republic, Switzerland, Uruguay, and Venezuela.
Authoritative Research on the Latin America In Vitro Diagnostics Market – Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.